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ABSTRACT 
Objective: This work involves investigation and evaluation of the factors that affect the preparation and the release of the model class II drug 
(erythromycin) to optimize the efficiency of its prepared nanocubosomal dispersion to give very fast initial burst effect within the first hour that can 
continue for further two hours. 
Methods: The work involved preparation of ten formulas of cubosomal dispersion by emulsifying different concentrations of glyceryl monooleate 
(GMO) (lipid content)/surfactant mixtures which were nano-sized and characterized morphologically by Transmission electronic microscopic 
(TEM), zeta potential, particle size, polydispersity index (pdI), pH, entrapment efficiency, conductivity test, dilution test and in vitro drug release. 
Results: The selected nanocubosomal formula (F1) showed pH (7.41), particle size (315.05 nm), pdI (0.194), zeta potential (-30.852), entrapment 
efficiency (91%) and gave a 70% drug release within the first hour of the in vitro test and continued until it gave 96.3% drug release with further 2 h. 
Conclusion: this work succeeded in preparing optimized cubosomal dispersion for erythromycin using different GMO/poloxamer 407 percent. The 
optimum formula gave an immediate release of the model drug (erythromycin) and it was ready to be incorporated in any suitable dosage form to 
give fast onset of action.  
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Development of colloidal carriers as delivery systems for pharma-
ceutical drugs has stimulated an exponential growth for the 
encapsulation of bioactive drug molecules into relatively non-toxic 
and inert carriers for the in vivo delivery constitutes a promising 
approach for the improvement of their therapeutic index while 
reducing the side effects [1]. Exceptional success has been made to 
improve efficacy by developing lipid-based carriers. Cubosomes are 
structured liquid crystalline particles, composed from certain 
amphiphilic lipids in definite proportions. It consists of lipid bilayers 
that are organized in three dimensions as honeycombed structures 
and divided into two internal aqueous channels that can be used by 
various bioactive ingredients, such as chemical drugs, peptides and 
proteins [2]. Due to their unique properties such as thermodynamic 
stability, bio adhesion, the ability to encapsulate hydrophilic, 
hydrophobic and amphiphilic substances, and the potential for 
controlled release through functionalization, cubosomes are 
regarded as promising vehicles for different routes of administration 
[3]. Cubosomes are made by the self-assembly of low molecular 
weight lipids. These lipids are characterized by a maximum 
continuous interface and high interface to volume ratio, which 
makes them promising candidates as efficient adsorbents and host-
guest applications [4]. The most characterized system of 
bicontinuous cubic phase forming lipid is the glyceryl monooleate 
(GMO)/water system. Monoglycerides are non-toxic, biodegradable 
and biocompatible materials that can self-associate depending on 
the temperature and aqueous forming content. In this work a model 
drug (erythromycin) was used which is used to treat bacteria 
responsible of the skin and upper respiratory tract infections, 
including Staphylococcus, Streptococcus, Corynebacterium and 
Haemophilus genera [5]. The aim of this work was to optimize the 
cubosomal dispersion of the model drug through studying different 
variables including using different ratios GMO: Smix, type and time 
of stirring to improve loading capacity and by enhancing penetration 
of the drug through skin barrier and improving its effectiveness. The 
release of the drug that may improve patient compliance through its 
quick relieve of different bacterial infections. 
MATERIALS AND METHODS 
Materials 
Erythromycin powder and poloxamer 407 was purchased from Sigma-
Aldrich, Chemie GMBH, Germany, Glyceryl mono oleate was purchased 
from Hangzhou Hyper chemicals, China, Potassium phosphate 
monobasic and Sodium hydroxide were purchased from Himedia, India. 
 
Table 1: Composition of the prepared nano cubosomal dispersion formulas 
Formula code GMO Poloxamer 407 Drug Buffer 
F1 4.4% 0.6% 2% q. s 
F2 4.2% 0.8% 2% q. s 
F3 4.0% 1.0% 2% q. s 
F4 3.8% 1.2% 2% q. s 
F5 3.6% 1.4% 2% q. s 
F6 3.4% 1.6% 2% q. s 
F7 3.2% 1.8% 2% q. s 
F8 3.0% 2.0% 2% q. s 
F9 2.8% 2.2% 2% q. s 
F10 2.6% 2.4% 2% q. s 
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Preparation of cubosomal dispersion formulas 
Preparation of cubosome dispersions formulas was done by 
emulsification of Glyceryl mono oleate (GMO)/surfactant mixtures. 
Poloxamer 407 was used as the nonionic surfactant in a concentration 
range between 0% and 16% w/w. The concentration of the 
GMO/Poloxamer mixture was 5% w/w with respect to the weight of the 
dispersion (table 1). Erythromycin concentration used was 2%. GMO 
and Poloxamer 407 were melted on a hot plate and then erythromycin 
was dispersed in the molten mixture. The molten mixture was then 
added drop by drop to the aqueous phase (phosphate buffer 7.4) at 70 ° 
C under mechanical stirring at 1500 rpm. The dispersions were 
maintained under mechanical stirring and they were cooled to room 
temperature to solidify the lipid droplets. The dispersions were 
sonicated for 10 min using probe ultrasonicator at 300 w in order to 
reduce the droplet size to the nanoscale then they were stored in glass 
bottles at room temperature (25 ° C) for further investigations [6, 7]. 
The physical appearance of the formulas 
Evaluation of the physical properties (color and homogeneity) for all 
the prepared nanocubosomal dispersion formulas (F1-F10) was 
done visually. 
pH determination of the formulas 
The pH of the formulations (F1-F10) was determined using a digital 
pH meter by immersing the electrode of the device in a beaker 
containing 10 ml of each of the nano cubosomal dispersion formulas 
and record the results after two minutes. 
Zeta potential, particle size and polydispersity index 
determination 
Measurement of the mean particle size (mean diameter), zeta potential 
(particle surface charge) and polydispersity index (size range of 
particles) was done by using dynamic light scattering method (ZetaPlus 
Particle Sizing), by this technique the light scattering fluctuations were 
examined, this fluctuation is due to the Brownian motion of cubosomal 
dispersion particles. It measures the size accurately in the range of 0.3 
nm to 10 μm. One ml of the diluted cubosomal dispersion was injected 
into folded capillary zeta cell and monitor the light scattering at 25 ° C 
(190 ° angle). The average particle size, polydispersity index, and zeta 
potential values for (F1-F10) were recorded [8]. 
Separation test  
This test is very important to check the physical stability of the 
dispersions. The centrifugation of each nanocubosomal dispersion 
formula (F1-F10) for 30 min at (10,000 rpm) was applied to check 
the nanocubosomal dispersions resistance for separation [8].  
Drug content 
Accurately, one ml of each nano cubosomal dispersion formula (F1-
F10) (containing 20 mg/ml erythromycin) was transferred to a 
volumetric flask (100 ml) and 70 ml methanol was appended, and 
the clear solution was achieved after sonication for 30 min. The 
solution volume was diluted with methanol to 100 ml and subjected 
to centrifugation for 15 min at 3000 rpm then filtered using 
Millipore filter 0.22 μm. The content of erythromycin was 
determined spectrophotometrically using the UV-Visible spectro-
photometer (Shimadzu 1650 PC-Japan) at λ max 285 nm [9].  
Entrapment efficiency 
For the determination of loading capacity (entrapment efficiency), each 
of the cubosomal dispersions (F1-F10) were subjected for centrifugation 
at 15000 rpm for a period of 30 min, and the supernatant liquid was 
collected, diluted appropriately and estimated using UV visible 
spectrophotometer at λ max 285 nm [10]. The percent of entrapment 
efficiency (%EE) was calculated by the following equation:  
%EE =
total drug − free drug
total drug
 × 100 
Conductivity test 
Electrical conductivity measurement was done to determine the 
nature of the prepared nanocubosomal dispersion formulas (F1-
F10). If the external (continuous) phase is aqueous, the 
nanocubosomal dispersions are o/w (high conduction) but if the 
internal (dispersal) phase is aqueous, the nanocubosomal 
dispersions are w/o (no conduction). Measuring of electrical 
conductivity (σ) was made by the use of a conductometer via 
immersing the conductometer probe in 10 ml of the prepared 
dispersion in a beaker at room temperature and the apparatus will 
register the results in μs/cm [11]. 
Dilution test 
The dilution test was done to check the physical stability of 
nanocubosomal dispersion formulas (F1-F10). The aqueous dilution 
test was carried out by diluting 1 ml of each nanocubosomal 
dispersion formula to 50 ml, 100 ml, and 500 ml with double 
distilled water at 37 ° C with constant stirring at a speed of 50 rpm 
and observed visually the clarity, turbidity, cracking and phase 
separation [12]. 
TEM study 
The nano cubosomal dispersions were further characterized by TEM 
operating at 30 Kilovolts. A drop of the diluted formula was allowed 
to be deposited on the circular copper film grid of 300 mesh and 
then stained with formvar and left for drying. The size and shape of 
the cubosomes were measured after the complete drying of the slide 
by observing the slide under the microscope [13]. 
In vitro release 
The release of erythromycin from the nano cubosomal dispersion 
formulas (F1-F10) was done by using dialysis membrane (MWCO 
2000 Da). Rotating paddle dissolution apparatus type II was used to 
measure the in vitro drug release from all prepared formulas. The 
sealed dialysis bag containing nanocubosomal dispersion formula 
(equivalent to 120 mg erythromycin) was sunken in 500 ml 
phosphate buffered (pH 7.4 dissolution media) with a speed of 50 
rpm. The temperature of the medium was maintained at 37±0.5 ° C. 
Five ml aliquots outgoing for suitable time periods and immediately 
making the replacement with fresh dissolution medium. The drug 
content in the withdrawn sample was determined spectro-
photometrically by using a UV-Vis spectrophotometer at the selected 
λ max 285 [14]. 
FTIR study 
The FTIR spectrum of the dispersions in comparison with the pure 
drug was recorded by the use of an FT-IR spectrophotometer. They 
were obtained using liquid cell by dripping several drops of the 
sample onto NaCl or KBr aperture plate and then sandwiching it 
under another aperture plate so that no gas bubbles are trapped. 
The thickness can be adjusted according to the sample absorbance 
by appropriately tightening the screws or by inserting spacers 
between the aperture plates [15]. 
RESULTS AND DISCUSSION 
Physical appearance 
All the formulas (F1-F10) appeared as a white homogenous milky 
solution without any aggregates. 
pH determination 
The pH of the nano cubosomes formulations (F1-F10) was measured 
using pH meter. The pH values were ranged (7.29-7.42), and this 
matches the skin requirements for topical preparations to avoid skin 
irritation and agreed with the results obtained with topical 
cubosomal gel for ketoconazole [17]. 
Zeta potential, particle size, and PDI determination 
Particle size measurement was carried out to confirm that all 
particles of the dispersion are in the nanometer size range (fig. 1). 
The effective diameter of all cubosomal dispersions was in the 
nanometer range (average particle size values ranged from 315 nm 
to 416 nm), with a polydispersity index of<1, the low value of 
polydispersity index 0.08-0.7 is considered to be desirable for 
uniform distribution and homogeneity of nano-sized particles within 
the preparation. While pdI value>0.7 to less than 1 is considered to 
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have a broad distribution of particle size [18]. The zeta potential of 
all formulas were comparably low, ranging between (-24.786 to-
30.852 mV), which could be due to the absence of charge in 
cubosomal dispersion ingredients, this is mainly because of the use 
of non-ionic surfactant (poloxamer 407) and the presence of fatty 
acid (oleic acid oil) which generally made the surface charge of the 
particle negative [19], the effect of zeta potential on the stability of 
nanoparticle was explained by rule of thumb. This rule states that 
values of zeta potential in the range (≤-30mV) to (≥+30mV) indicate 
that there are good stability and values in the range (≤-60mV) to 
(≥+60mV) indicate that there is excellent stability in the formulation 
[20]. For nonionic surfactant (poloxamer 407) that act by steric 
stabilization, the value of zeta potential of 20mV or even lower 
provided an efficient stabilization due to that the non-ionic 
surfactant (poloxamer 407) provided good steric stability for 
maintaining the stability of single layer nanodispersions [21]. 
 
 
Fig. 1: Particle size distribution by number of the selected formula (F1) 
 
Separation test  
No sedimentation, creaming or phase separation upon 
centrifugation for all the prepared nano cubosomal dispersion 
formulas (F1-F10) was observed, this is a good indication of their 
high stability [22]. This proved that the thermal motion of the 
dispersion droplets (the Brownian motion) exceeded the external 
forces such as centrifugation and/or gravitation [23]. 
Drug content 
The drug content of all nano cubosomal dispersion formulas (F1-F10) 
results are inconsistent with the requirements of the USP(16), indicating 
high adequacy of the preparation method and high content uniformity of 
the prepared formulas, where all the prepared nano cubosomal 
dispersions have a drug content between (90-98%) and this agreed with 
the acceptable range according to the USP (85-115%) [24]. 
Entrapment efficiency 
The entrapment efficiency of erythromycin nano cubosomal 
dispersion formulas is shown in fig. (2). The high entrapment 
efficiency indicates that the technique applied in the preparation of 
nanoparticles is applicable and reliable. The entrapment efficiency 
of (F1-F5) is higher than the entrapment efficiency of (F6-F10) due 
to the presence of high percent of lipid content (GMO), and as the 
percent of lipid (GMO) was decreased the entrapment efficiency 
decreased too, this is mainly due to the high solubility of the drug 
(erythromycin) in the lipid part of the dispersion. This agreed with 
Etoposide-loaded nanoparticles made from glyceride lipids [25]. 
 
 
Fig. 2: Entrapment efficiency of erythromycin nano cubosomal dispersion formulas, (values are mean±SD) (n=3) 
 
Conductivity test 
The electrical conductivity (σ) of nanocubosomal dispersions 
defined as a measurement of materials ability to confirm the 
transport of an electric charge and it was measured to determine the 
nature or type of the external phase of dispersion and to detect the 
phase inversion phenomena. Conductivity measurement depends on 
the higher conductivity of the water compared to the oil and gives 
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high values in o/w dispersions where water is the external phase. 
The results indicated that all the prepared nanocubosomal 
dispersion formulas were o/w type since high conductivity (76-
252μs/cm). The higher conductivity is due to a large percentage of 
water, which allows higher freedom for mobility of ions [26]. 
Dilution test 
The dilution test is very important to define whether the 
dispersion is o/w or w/o. If the emulsion is o/w type then the 
addition of more continuous phase (water) will not cause cracking 
or separation of that emulsion. The results showed that the 
addition of water to all nanocubosomal dispersion formulas (F1-
F10) showed clear nanocubosomal dispersion in less than 1 
minute with no cracking or separation adding a further indication 
that they are all o/w type [27]. 
TEM study 
The shape and size of the nano cubosomal dispersions were 
characterized by the use of transmission electron microscopy (TEM) 
as in fig. (3). The images showed cubosomes as dark globules with 
bright surrounding with average droplet size (375 nm) and similar 
shape was obtained with transdermal cubosomes of Etodolac [28]. 
 
 
Fig. 3: (A) TEM picture at zoom 64000 pixels, (B) TEM picture at zoom 180000 pixels 
 
In vitro dissolution test  
The cumulative percentage of erythromycin at different time intervals 
for each nano cubosomal dispersion is shown in fig. (4). The result of 
cumulative drug release showed that different GMO content had a 
profound effect on drug release. The result showed a significant decrease 
in the initial drug release (after 1 h.) between F1 and F10, 70% and 45% 
respectively. Also, the release after 3 h was significantly greater for F1 
than F10, 96% and 89 % respectively. As the concentration changed 
from the higher concentration of GMO in F1 (4.4%) to the lower 
concentration of GMO in F10 (2.6%). In addition to that, the 
concentration of poloxamer 407 in F10 is much higher than F1 and that 
caused a significant decrease in the release of the drug from F10 in 
comparison to F1, since this will be fewer water channels resulting for 
reinforcement of micellar structure [29, 30]. The result showed that F1 
gave 70% drug release within 1 h and the release increasingly continued 
for the next 2 h (96.3%), which was better than other formulas, and this 






Fig. 4: (A) In vitro release profile of erythromycin from (F1-F5) formulas (values are mean±SD) (n=3), in phosphate buffer solution (pH 
7.4) at 37±1 °C, (B) In vitro release profile of erythromycin from F6-F10 formulas (values are mean±SD) (n=3), in phosphate buffer 
solution (pH 7.4) at 37±1 °C 
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The FT-IR spectrum of the pure drug showed the distinctive peaks 
values, which are 1639 cm-1 C=O (carbonyl stretching), 3402 cm-1 
C-OH (alcohol stretching) and 1085 cm-1 C-O-C (ether stretching). 
The FTIR spectrum of erythromycin nanocubosomal dispersion 
displayed same functional groups band with very slight shifting 
indicating excellent compatibility of excipients with the drug [32]. 
CONCLUSION 
Depending on the results obtained in this study, this work revealed 
that slight change in lipid: surfactant ratio as well as using 
alternative stirring type and time in comparison to related 
preparation led to improving entrapment efficiency and gave 
immediate release of the drug from the prepared emulsions as well 
as the unique structure of the prepared cubosomes that can improve 
the antibacterial activity of the model drug and can give quick 
significant action that will improve patient compliance. 
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